Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

TON - August 2020, Vol 13, No 4

TON June 2020, Vol 13, No 3 Cover

The Cedars-Sinai Blood & Marrow Transplant (BMT) Program, Los Angeles, CA, has performed more than 2200 stem-cell and bone marrow transplants since its inception in 1990.
Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting.
Miami, FL—With too much red tape regarding genetic (ie, hereditary) testing, not enough people are being identified before they have breast cancer, according to Kevin Hughes, MD, FACS, Co-Director, Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Boston.
Oncology nurses and nurse navigators are positioned on the front lines of care, playing an integral role in patients’ battles against cancer.
My first column as Editor-in-Chief was written for the inaugural issue of this publication, which was originally called The Oncology Nurse.
The COVID-19 pandemic is stretching into its fifth month in the United States, and patient advocacy groups continue to focus on providing the necessary support and services to patients with cancer.
Preliminary results from a single-arm study demonstrated promising progression-free survival (PFS) and a clinically meaningful objective response rate (ORR) with the combination of pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane) as second- or third-line therapy in patients with advanced urothelial carcinoma.
Circulating tumor DNA (ctDNA) analysis is a useful sequencing platform in metastatic castration-resistant prostate cancer (CRPC), and ctDNA alterations are detected in most patients with this type of prostate cancer, according to Justin Shaya, MD, Hematology/Oncology Fellow, UC San Diego Moores Cancer Center, CA.
There has been increased focus on the study of tumor alterations that may predict treatment benefit or serve as possible actionable targets for new therapeutic approaches in cancer.
As the complexity of cancer care continues to evolve, adhering to evidence-based treatment guidelines is a growing challenge for oncologists. The use of clinical decision support tools within the electronic health record (EHR) system can boost provider compliance and drive quality improvement, according to data presented at the ASCO 2020 virtual annual meeting.
Page 1 of 3
Results 1 - 10 of 27